DK4455141T3 - Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes - Google Patents

Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes

Info

Publication number
DK4455141T3
DK4455141T3 DK22910193.6T DK22910193T DK4455141T3 DK 4455141 T3 DK4455141 T3 DK 4455141T3 DK 22910193 T DK22910193 T DK 22910193T DK 4455141 T3 DK4455141 T3 DK 4455141T3
Authority
DK
Denmark
Prior art keywords
glp
pharmaceutically acceptable
acceptable salt
crystalline form
receptor agonist
Prior art date
Application number
DK22910193.6T
Other languages
Danish (da)
English (en)
Inventor
Weidong Lu
Gujun Xu
Junran Yang
Qiyun Shao
Zhenxing Du
Jun Feng
Feng He
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of DK4455141T3 publication Critical patent/DK4455141T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK22910193.6T 2021-12-23 2022-12-23 Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes DK4455141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111584574 2021-12-23
PCT/CN2022/141418 WO2023116882A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
DK4455141T3 true DK4455141T3 (da) 2026-04-27

Family

ID=86901360

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22910193.6T DK4455141T3 (da) 2021-12-23 2022-12-23 Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes

Country Status (11)

Country Link
US (1) US20250049777A1 (enExample)
EP (2) EP4455141B1 (enExample)
JP (1) JP2024547113A (enExample)
KR (1) KR20240125003A (enExample)
CN (1) CN118434730A (enExample)
AU (1) AU2022418658A1 (enExample)
CA (1) CA3241670A1 (enExample)
DK (1) DK4455141T3 (enExample)
MX (1) MX2024007906A (enExample)
TW (1) TW202328114A (enExample)
WO (1) WO2023116882A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202535353A (zh) * 2024-01-09 2025-09-16 大陸商山東盛迪醫藥有限公司 一種ｇｌｐ－１ｒ激動劑醫藥組成物及其應用
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CU20210042A7 (es) * 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
EP4166142A4 (en) * 2020-06-10 2024-06-26 Medshine Discovery Inc. Methyl-substituted benzobisoxazole compound and use thereof
CN119930605A (zh) * 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022228490A1 (zh) * 2021-04-30 2022-11-03 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
WO2023116882A1 (zh) 2023-06-29
MX2024007906A (es) 2024-07-10
KR20240125003A (ko) 2024-08-19
AU2022418658A1 (en) 2024-07-11
CN118434730A (zh) 2024-08-02
CA3241670A1 (en) 2023-06-29
TW202328114A (zh) 2023-07-16
EP4455141A4 (en) 2025-04-09
JP2024547113A (ja) 2024-12-26
EP4455141A1 (en) 2024-10-30
US20250049777A1 (en) 2025-02-13
EP4455141B1 (en) 2026-03-25
EP4732838A2 (en) 2026-04-29

Similar Documents

Publication Publication Date Title
DK3841098T3 (da) Tropomyosin-receptor-kinase- (trk) nedbrydningsforbindelser og anvendelsesfremgangsmåder
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
JOP20210337B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
ZA202210199B (en) Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
DK4209490T3 (da) 2-(((2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1h-benzo[d]imidazol-6-carboxylsyrederivater og lignende forbindelser som glp-1-modulatorer til behandling af diabetes
EP4141008A4 (en) PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR
EP4130005A4 (en) CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
UA118239C2 (uk) Сполука-коагоніст gip і glp-1
DK4508045T3 (da) Citratsalt-former af en muskarinreceptor-agonist
EP3700550A4 (en) LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
EP4455141A4 (en) PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PROCESS FOR PREPARATION THEREOF
SI3826662T1 (sl) Metoda uporabe so-agonista gip/glp1 za sladkorno bolezen
EP4442700A4 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
LT4076652T (lt) Farmaciniu požiūriu priimtina atrasentano druska, skirta naudoti iga nefropatijos gydymo būdui
EP4317179A4 (en) GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION AND USE
EP3610875A4 (en) OPIOID RECEPTOR (MOR) -AGONISTIC SALT, FUMARATE SALT-I CRYSTAL SHAPE THEREOF, AND PRODUCTION METHOD THEREOF
DK4038063T3 (da) Heterocykliske forbindelser til inhibering af tyk2-aktiviteter
SG11202102586RA (en) Crystalline forms of a farnesoid x receptor agonist
PL4289824T3 (pl) Związek uracylowy zawierający fragment karboksylanowy i sposób jego przygotowania, kompozycja chwastobójcza i zastosowanie
DK4114826T3 (da) Krystallinske former af en farmaceutisk forbindelse
EP4159722A4 (en) METHOD FOR PREPARING GLP-1 RECEPTOR AGONIST
IL325358A (en) Heterocyclic glp-1 agonists
LT3456340T (lt) Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
MX2020005332A (es) Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion.
EP4201935A4 (en) Crystal of compound x7 hydrochloride, preparation method therefor and use thereof